DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE

Scripps Institution Of Oceanography, La Jolla CA

Investigators

Abstract

“Prevention is better than cure”, is the motive behind the vaccines for infectious diseases. Current vaccines for influenza need help as they are only effective for short durations, particularly in elderly individuals and patients with chronic diseases. Also, new vaccines must be prepared yearly to protect against new strains of influenza virus. Thus, there is substantial demand for the development of new immune boosting adjuvants to improve existing influenza vaccines. Our contract supports the development of a new vaccine adjuvant, Fos47, that improves vaccines durability and cross-protection in animal models. The protective efficacy of vaccine adjuvant Fos47 will be assessed in influenza virus challenge models to identify an optimal dosage, route and frequency of immunization. The vaccine adjuvant will be prepared in a large scale for the initiation of human clinical trials.